Florica Therapeutics

Executive Summary

Florica Therapeutics is a Cambridge-based biotechnology company founded in 2018, dedicated to developing small molecule therapeutics that disrupt protein-protein interactions (PPIs) for oncology. The company aims to tackle historically 'undruggable' intracellular targets by leveraging novel approaches to PPI modulation. While still in early preclinical stages, Florica's platform holds promise for addressing challenging cancer targets that have eluded conventional drug discovery. The company's focus on small molecules offers advantages in cell permeability and oral bioavailability compared to larger biologics. Given the high unmet need in targeting PPIs, Florica's technology could potentially unlock new therapeutic avenues in oncology, though it remains at a nascent stage with no disclosed pipeline candidates or public funding details.

Upcoming Catalysts (preview)

• Q3 2026Lead optimization completion and candidate nomination40% success
• TBDInitiation of IND-enabling studies30% success
• Q4 2026Announcement of a strategic partnership or licensing deal20% success